Univariate transfusion risk factors for TRALI
| Transfusion factor assessed for each patient . | OR . | Lower 95% CI . | Upper 95% CI . | P . |
|---|---|---|---|---|
| Blood or blood component(s) received | ||||
| Plasma from female donor | 3.0 | 1.44 | 6.3 | .004 |
| Plasma from previously pregnant female donor | 2.2 | 1.08 | 4.6 | .03 |
| Platelets from previously pregnant female donor | 2.5 | 1.19 | 5.4 | .02 |
| Cryoprecipitate from female donor | 5.5 | 1.41 | 21.4 | .014 |
| Cryoprecipitate from previously pregnant female donor | 5.8 | 1.49 | 22.5 | .014 |
| MICA antibody, sum of amounts in all units received | ||||
| MICA antibody | 1.28 | 1.08 | 1.53 | .006 |
| LysoPC and cytokines: sum of amounts (concentration × volume) in all units received | ||||
| LysoPC | 1.27 | 1.07 | 1.51 | .006 |
| IL1ra | 1.12 | 1.01 | 1.24 | .04 |
| IL1b | 1.19 | 1.03 | 1.36 | .02 |
| VEGF | 1.04 | 1.00 | 1.08 | .03 |
| Neutrophil priming activity: sum of amounts (% neutrophils positive for CD11b up-regulation × volume) in all units received | ||||
| CD11b up-regulation | 1.04 | 1.01 | 1.07 | .008 |
| Transfusion factor assessed for each patient . | OR . | Lower 95% CI . | Upper 95% CI . | P . |
|---|---|---|---|---|
| Blood or blood component(s) received | ||||
| Plasma from female donor | 3.0 | 1.44 | 6.3 | .004 |
| Plasma from previously pregnant female donor | 2.2 | 1.08 | 4.6 | .03 |
| Platelets from previously pregnant female donor | 2.5 | 1.19 | 5.4 | .02 |
| Cryoprecipitate from female donor | 5.5 | 1.41 | 21.4 | .014 |
| Cryoprecipitate from previously pregnant female donor | 5.8 | 1.49 | 22.5 | .014 |
| MICA antibody, sum of amounts in all units received | ||||
| MICA antibody | 1.28 | 1.08 | 1.53 | .006 |
| LysoPC and cytokines: sum of amounts (concentration × volume) in all units received | ||||
| LysoPC | 1.27 | 1.07 | 1.51 | .006 |
| IL1ra | 1.12 | 1.01 | 1.24 | .04 |
| IL1b | 1.19 | 1.03 | 1.36 | .02 |
| VEGF | 1.04 | 1.00 | 1.08 | .03 |
| Neutrophil priming activity: sum of amounts (% neutrophils positive for CD11b up-regulation × volume) in all units received | ||||
| CD11b up-regulation | 1.04 | 1.01 | 1.07 | .008 |
Numbers of patients who received or did not receive this transfusion risk factor are not available because multiple imputation was used for units with missing data (“Statistical methods: risk factor analysis”). Other not statistically significant univariate transfusion risk factors are described in Table 10. Univariate antibody factors are not described in this table, but univariate anti-HLA factors are described in supplemental Table 8, and anti-HNA factors are described in supplemental Table 9.